Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pharmaxis Ltd (AU:SNT)
ASX:SNT
Holding AU:SNT?
Track your performance easily
SNT Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.01 - AU$0.08
Previous CloseN/A
Volume5.35M
Average Volume (3M)6.23M
Market Cap
AU$118.43M
Enterprise ValueAU$23.38M
Total Cash (Recent Filing)$21.50M
Total Debt (Recent Filing)$8.27M
Price to Earnings (P/E)―
Beta2.77
Next Earnings
Feb 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,579,112,900
10 Day Avg. Volume2,520,494
30 Day Avg. Volume6,225,284
Standard Deviation0.18
R-Squared0.02
Alpha0.00090
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)13.13
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.15
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Pharmaxis Ltd News
PremiumCompany Announcements
Syntara Limited Seeks Shareholder Approval for $15M Capital Raise
PremiumCompany Announcements
Syntara Limited Announces New Securities Issue Plan
PremiumCompany Announcements
Syntara Limited to Issue 250 Million Shares
PremiumCompany Announcements
Pharmaxis Ltd Announces New Equity Raising Initiative
PremiumCompany Announcements
Syntara Ltd Secures A$15 Million for Clinical TrialsPremiumCompany Announcements
Syntara Limited’s SNT-5505 Shows Promise in Myelofibrosis Trial
PremiumCompany Announcements
Syntara Prepares to Unveil Promising Myelofibrosis DataPremiumCompany Announcements
Syntara Limited Prepares for Interim Trial Data ReleaseOptions Prices
Currently, No data available
---
Ownership Overview
SNT FAQ
What was Pharmaxis Ltd’s price range in the past 12 months?
Pharmaxis Ltd lowest share price was AU$0.01 and its highest was AU$0.08 in the past 12 months.
What is Pharmaxis Ltd’s market cap?
Pharmaxis Ltd’s market cap is AU$118.43M.
When is Pharmaxis Ltd’s upcoming earnings report date?
Pharmaxis Ltd’s upcoming earnings report date is Feb 07, 2025 which is in 19 days.
How were Pharmaxis Ltd’s earnings last quarter?
Pharmaxis Ltd released its earnings results on Aug 30, 2024. The company reported -AU$0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.014.
Is Pharmaxis Ltd overvalued?
According to Wall Street analysts Pharmaxis Ltd’s price is currently Overvalued.
Does Pharmaxis Ltd pay dividends?
Pharmaxis Ltd does not currently pay dividends.
What is Pharmaxis Ltd’s EPS estimate?
Pharmaxis Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaxis Ltd have?
Pharmaxis Ltd has 1,579,112,900 shares outstanding.
What happened to Pharmaxis Ltd’s price movement after its last earnings report?
Pharmaxis Ltd reported an EPS of -AU$0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -25%.
Which hedge fund is a major shareholder of Pharmaxis Ltd?
Currently, no hedge funds are holding shares in AU:SNT
---
Pharmaxis Ltd Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
284.21%
12-Months-Change
Fundamentals
Return on Equity
-191.95%
Trailing 12-Months
Asset Growth
-56.79%
Trailing 12-Months
Company Description
Pharmaxis Ltd
Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.
---
Technical Analysis
PYC Therapeutics Limited
―
Aroa Biosurgery Ltd
―
LBT Innovations Limited
―
Althea Group Holdings Ltd.
―
Bod Australia Ltd
―
---